Drug application
ALEVE (NAPROXEN SODIUM)
Drugs@FDA NDA 020204 · BAYER
Key facts
| Drug name | ALEVE |
|---|---|
| Active ingredients | NAPROXEN SODIUM |
| Application type | NDA |
| Application number | 020204 |
| Company | BAYER |
| Dosage forms | TABLET, ORAL |
| Strength | 220MG |
| Marketing status | Over-the-counter |
| Reference listed drug | Yes |
| Latest submission class | Type 3 - New Dosage Form |
| Latest submission status date | Jan 11, 1994 |
At a glance
- 1–9 Submissions
- 10–99 Supplements
- 10–99 Label versions
- 1–9 Products
- None Therapeutic equivalents
- No FDA letters on file
- No FDA reviews on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: